# HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

> **NCT02143830** · PHASE2 · RECRUITING · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 70 (estimated)

## Conditions studied

- Fanconi Anemia
- Severe Marrow Failure
- Myelodysplastic Syndrome (MDS)
- Acute Myelogenous Leukemia (AML)

## Interventions

- **DRUG:** Busulfan
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** rabbit ATG
- **DRUG:** G-CSF
- **BIOLOGICAL:** Peripheral blood stem cell

## Key facts

- **NCT ID:** NCT02143830
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2014-04
- **Primary completion:** 2026-12
- **Final completion:** 2028-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-11-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02143830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02143830, "HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02143830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*